The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Part B - Final decisions on matters not referred to an expert advisory committee
4. New Chemical Entities - medicines for human therapeutic use
4.1. Galcanezumab
Note
New text is shown as green, larger font, with a horizontal line above it.
Delegate's final decision
Final decision
The delegate's final decision is to amend the Poisons Standard to include galcanezumab in Schedule 4 as follows:
Schedule 4 - New Entry
GALCANEZUMAB
Index - New Entry
GALCANEZUMAB
Schedule 4
Implementation date
1 June 2019
Reasons
The matters under subsection 52E (1) of the Therapeutic Goods Act 1989 considered relevant by the delegate for the decision include:
- the risks and benefits of the use of a substance:
It is a new chemical entity with no clinical or marketing experience in Australia.
- the purposes for which a substance is to be used and the extent of use of a substance:
Migraine prophylaxis requires medical assessment and monitoring.
- the toxicity of a substance:
Potential toxicity is not known.
- the dosage, formulation, labelling, packaging and presentation of a substance:
Substance requires subcutaneous injection
- the potential for abuse of a substance:
Nil
- any other matters that the Secretary considers necessary to protect public health:
Nil
Scheduling proposal
The delegate of the Secretary proposed to amend the Poisons Standard with respect to galcanezumab, a new chemical entity (NCE) for a human therapeutic medicine.
Scheduling status
Galcanezumab is not specifically scheduled in the Poisons Standard but as it is a monoclonal antibody, galcanezumab is captured by the Schedule 4 entry for monoclonal antibodies as follows:
Schedule 4
MONOCLONAL ANTIBODIES for therapeutic use except:
- in diagnostic test kits; or
- when separately specified in these Schedules.
Delegate's considerations
- Section 52E(1) of the Therapeutic Goods Act 1989;
- Scheduling Policy Framework (SPF 2018); and
- Advice on the place in therapy of this NCE.